Research output: Contribution to journal › Review article › peer-review
Стеатогепатиты смешанного генеза : больше вопросов, чем ответов (часть 2). / Raikhelson, Karina L.; Kondrashina, Elina A.; Pazenko, Ekaterina V.
In: Terapevticheskii Arkhiv, Vol. 93, No. 4, 15.04.2021, p. 516-520.Research output: Contribution to journal › Review article › peer-review
}
TY - JOUR
T1 - Стеатогепатиты смешанного генеза
T2 - больше вопросов, чем ответов (часть 2)
AU - Raikhelson, Karina L.
AU - Kondrashina, Elina A.
AU - Pazenko, Ekaterina V.
N1 - Райхельсон К.Л., Кондрашина Э.А., Пазенко Е.В. Стеатогепатиты смешанного генеза: больше вопросов, чем ответов (часть 2) // Терапевтический архив. - 2021. - Т. 93. - №4. - C. 516-520. doi: 10.26442/00403660.2021.04.200755 Raikhelson K.L., Kondrashina E.A., Pazenko E.V. Mixed steatohepatitis: more questions than answers (part 2) // Terapevticheskii arkhiv. - 2021. - Vol. 93. - N. 4. - P. 516-520. doi: 10.26442/00403660.2021.04.200755
PY - 2021/4/15
Y1 - 2021/4/15
N2 - In this review, we discussed the epidemiological and pathogenetic aspects of mixed steatohepatitis (SH), developed due to non-alcoholic fatty liver disease, metabolic associated fatty liver disease, drug-induced liver injury. We discussed the mechanisms of the mutually aggravating influence of etiological factors. Drugs can cause steatosis and SH, as well as contribute to the progressive course of existing SH, primarily of metabolic origin. The issues of interaction of pathogenetic factors, peculiarities of diagnostics and perspectives of pathogenetic and symptomatic treatment are considered. Therapy of mixed SH is based on avoidance of hepatotoxic drugs and lifestyle modification, medications with demonstrated efficacy (such as ademetionine) in certain SH might be used.
AB - In this review, we discussed the epidemiological and pathogenetic aspects of mixed steatohepatitis (SH), developed due to non-alcoholic fatty liver disease, metabolic associated fatty liver disease, drug-induced liver injury. We discussed the mechanisms of the mutually aggravating influence of etiological factors. Drugs can cause steatosis and SH, as well as contribute to the progressive course of existing SH, primarily of metabolic origin. The issues of interaction of pathogenetic factors, peculiarities of diagnostics and perspectives of pathogenetic and symptomatic treatment are considered. Therapy of mixed SH is based on avoidance of hepatotoxic drugs and lifestyle modification, medications with demonstrated efficacy (such as ademetionine) in certain SH might be used.
KW - Ademetionine
KW - Drug-induced liver injury
KW - Metabolic associated fatty liver disease
KW - Non-alcoholic fatty liver disease
KW - Steatohepatitis
KW - Ademetionine
KW - Drug-induced liver injury
KW - Metabolic associated fatty liver disease
KW - Non-alcoholic fatty liver disease
KW - Steatohepatitis
KW - FIBROSIS
KW - drug-induced liver injury
KW - steatohepatitis
KW - metabolic associated fatty liver disease
KW - RISK-FACTORS
KW - non-alcoholic fatty liver disease
KW - TAMOXIFEN
KW - METHOTREXATE
KW - NONALCOHOLIC STEATOHEPATITIS
KW - ACG CLINICAL GUIDELINE
KW - INDUCED LIVER-INJURY
KW - S-ADENOSYLMETHIONINE
KW - DISEASE
KW - MITOCHONDRIAL DYSFUNCTION
KW - ademetionine
UR - http://www.scopus.com/inward/record.url?scp=85107854260&partnerID=8YFLogxK
UR - https://www.mendeley.com/catalogue/c8bf512b-b0b5-3451-a089-76ab2b50189c/
U2 - 10.26442/00403660.2021.04.200755
DO - 10.26442/00403660.2021.04.200755
M3 - Обзорная статья
AN - SCOPUS:85107854260
VL - 93
SP - 516
EP - 520
JO - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)
JF - ТЕРАПЕВТИЧЕСКИЙ АРХИВ (TERAPEVTICHESKII ARKHIV)
SN - 0040-3660
IS - 4
ER -
ID: 78141107